GuidelineBritish journal of haematology2021
UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.
Guideline in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Systematic Review of PET/CT Utilization in Breast Implant-Associated Anaplastic Large Cell Lymphoma.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Article
- Implant surface selection in primary cosmetic breast augmentation: A national cross-sectional study of UK plastic surgeons.JPRAS open · 2025Article
- Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Anaplastic Large Cell Lymphoma Related to Breast Implant Presenting as a Solid mass: A Case Report.Case reports in surgery · 2025Article
- Secondary intact capsulectomy with seroma without implant: revision of an incomplete treatment of BIA-ALCL - a case report.Case reports in plastic surgery & hand surgery · 2025Article
- Comment on "Reply to Mortality Rate in Breast Implant Surgery: Is an Additional Procedure Worthwhile to Mitigate BIA-ALCL Risk".Aesthetic plastic surgery · 2023Article
- Oncoplastic and reconstructive breast surgery.Frontiers in oncology · 2023Review
- Anaplastic large cell lymphoma, ALK-negative of the breast diagnosed a short time after removal of breast implant in a patient with breast carcinoma: diagnostic and therapeutic considerations.BMJ case reports · 2022Article
- Reverse strategy to locally advanced breast implant-associated anaplastic large cell lymphoma: A case report.Frontiers in oncology · 2022Article
- Current Challenges in Breast Implantation.Medicina (Kaunas, Lithuania) · 2021Review
- MRI features of breast implant-associated anaplastic large cell lymphoma.The British journal of radiology · 2021Review
- Paraneoplastic acquired ichthyosis as the first manifestation in breast implant-associated anaplastic large cell lymphoma.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)-negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.